Europska Unija - švedski - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydroklorid - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Europska Unija - švedski - EMA (European Medicines Agency)

novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - hypertension - agenter som verkar på renin-angiotensinsystemet - behandling av essentiell hypertoni. exforge är indicerat för patienter vars blodtryck inte är adekvat kontrollerat om amlodipin eller valsartan monoterapi.

Europska Unija - švedski - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Europska Unija - švedski - EMA (European Medicines Agency)

novartis europharm limited - indakaterolmaleat - pulmonell sjukdom, kronisk obstruktiv - läkemedel mot obstruktiv lungsjukdom, - hirobriz breezhaler är indicerat för underhållsbronkodilatorns behandling av luftflödesobstruktion hos vuxna patienter med kronisk obstruktiv lungsjukdom.

Europska Unija - švedski - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (som fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastiska medel - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycytemi vera (pv)jakavi är indicerat för behandling av vuxna patienter med polycytemi vera som är resistenta eller intoleranta av hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Europska Unija - švedski - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 och 5. 1 för tillgänglig data på olika kombinationer).

Europska Unija - švedski - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ögonsjukdomar - lucentis är indicerat hos vuxna för behandling av neovaskulära (våt) åldersrelaterad makuladegeneration (amd)behandling av synnedsättning på grund av koroidal kärlnybildning (cnv)behandling av nedsatt syn på grund av diabetiska makulaödem ödem (dme)behandling av nedsatt syn på grund av makulaödem ödem sekundärt till retinal vein occlusion (branch rvo eller centrala rvo).

Europska Unija - švedski - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - hjärtsvikt - agenter som verkar på renin-angiotensinsystemet - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

Europska Unija - švedski - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromid - pulmonell sjukdom, kronisk obstruktiv - läkemedel mot obstruktiv lungsjukdom, - seebri breezhaler är indicerat som en underhållsbronkodilatorbehandling för att lindra symtom hos vuxna patienter med kronisk obstruktiv lungsjukdom (kol).

Europska Unija - švedski - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin hydroklorid - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.